Allotment results | Simcere Pharmacy-B (02410) 47.88% of IPO subscribers were successfully allotted at a final price of HKD 12.1
Tongyuan Kangyao Pharmaceutical-B (02410) placement ended.
On August 20th, the placement of Tongyuan Kangyao Pharmaceutical-B (02410) ended. The offer price was HK$12.1, and the final price was set at HK$12.1 per share, with each lot costing HK$6050.
For the public offering, there were 974 applicants, with a 47.88% allotment rate for one lot, and a subscription multiple of approximately 2.29 times. The number of international placement applicants was not disclosed, with a subscription multiple of approximately 1.01 times.
The number of international placement applicants was not disclosed, with an oversubscription multiple indicating moderate oversubscription.
 Related Articles 

TRANSMIT ENT(01326): Qian Shanshan has been appointed as an executive director.

QIDIAN GUOFENG (01280) issued 25.0206 million shares according to the stock incentive plan.

MOBI DEV (00947) repurchased 11,000 shares for 1806 Hong Kong dollars on October 31st.
TRANSMIT ENT(01326): Qian Shanshan has been appointed as an executive director.

QIDIAN GUOFENG (01280) issued 25.0206 million shares according to the stock incentive plan.

MOBI DEV (00947) repurchased 11,000 shares for 1806 Hong Kong dollars on October 31st.

RECOMMEND

First in History: NVIDIA’s Market Capitalization Tops $5 Trillion
30/10/2025

Congressional Budget Office Estimates Government Shutdown Has Cost the U.S. Economy $18 Billion
30/10/2025

Wall Street on China’s Internet Sector: Distinct Investment Opportunities in AI and Gaming; Caution on E‑commerce
30/10/2025


